STRATEGIC-1: multiple-line, randomized, open-label GERCOR-PRODIGE-39 phase III trial in unresectable RAS/BRAF wild-type metastatic colorectal cancer
Dominique Auby, Benoist Chibaudel, Olivier Dupuis, Emmanuel Maillard et al.
Journal
Signal Transduction and Targeted Therapy
Topics
Colorectal Cancer Treatments and Studies
article
STRATEGIC-1: multiple-line, randomized, open-label GERCOR-PRODIGE-39 phase III trial in unresectable RAS/BRAF wild-type metastatic colorectal cancer
Dominique Auby, Benoist Chibaudel, Olivier Dupuis, Emmanuel Maillard, Marie‐Line Garcia‐Larnicol, Pierre-Luc Etienne, Nabil Baba-Hamed, Jérôme Desrame, Louis-Marie Dourthe, Vincent Bourgeois, Olivier Romano, Julie Henriques, Christophe Tournigand, François Ghiringhelli, Christophe Louvet, Aimery de Gramont, Thierry André, Brian Healey Bird, Elisabeth Carola, Einat Shacham-Shmueli
article en
Abstract
No abstract available for this paper.
Publication Tag
Signal Transduction and Targeted TherapyVol. 11(1)
Institutions
Inserm (FR), Sheba Medical Center (IL), Bon Secours Hospital Cork (IE), Sorbonne Université (FR), Institute Mutualiste Montsouris (FR), Centre Georges François Leclerc (FR), Methodology and Quality of Life Unit in Oncology (FR), Assistance Publique – Hôpitaux de Paris (FR), Montagu Hospital (GB), GERCOR (France) (FR), Hôpital Privé Jean Mermo (FR), Hôpitaux Universitaires Henri-Mondor (FR), Centre Hospitalier Annecy Genevois (FR), Centre de Recherche Saint-Antoine (FR), Clinique Victor Hugo (FR), Hôpital Paris Saint-Joseph (FR), Institut Hospitalier Franco Britannique (FR), Université d'été de Boulogne-sur-Mer (FR), Centre Hospitalier Laennec (FR), École Centrale de Lille (FR)